Increased vulnerability to l-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Molecular Neuroscience

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1385/JMN:27:3:277PMID 16280597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.

  2003cited by this paper
• L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.

  2002cited by this paper
• Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.

  2001cited by this paper
• Does Levodopa Accelerate Parkinson’s Disease?

  1999cited by this paper
• Levodopa neurotoxicity

  1998cited by this paper
• VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

  1997cited by this paper
• Nigral type I astrocytes release a soluble factor that increases dopaminergic neuron survival through mechanisms distinct from basic fibroblast growth factor.

  1994cited by this paper
• Parkinson's disease.

  1994cited by this paper
• Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules.

  1994cited by this paper
• Ascorbic Acid in Mesencephalic Cultures: Effects on Dopaminergic Neuron Development

  1991cited by this paper
• Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

  1989cited by this paper
• Parkinson's disease

  1940cited by this paper

• Environmental noise-induced changes to the IC-SNc circuit promotes motor deficits and neuronal vulnerability in a mouse model of Parkinson’s Disease

  2025cites this paper
• A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease

  2022cites this paper
• Dopamine Homeostasis and Role of VMAT2 in Neurodegeneration

  2021cites this paper
• Decreased striatal vesicular monoamine transporter 2 (VMAT2) expression in a type 1 diabetic rat model: A longitudinal study using micro-PET/CT.

  2020cites this paper
• A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson’s Disease

  2020cites this paper
• Prolyl oligopeptidase and alpha-synuclein in the regulation of nigrostriatal dopaminergic neurotransmission

  2019cites this paper
• MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION

  2017cites this paper
• Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson’s disease motor symptoms without neuronal degeneration in adult mice

  2017cites this paper
• The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.

  2015cites this paper
• Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat.

  2015cites this paper
• Regulation of DA Homeostasis and Role of VMAT2 in DA-Induced Neurodegeneration

  2014cites this paper
• The vesicular monoamine transporter 2: an underexplored pharmacological target.

  2014cites this paper
• VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease

  2011cites this paper
• Monoamine transporters: vulnerable and vital doorkeepers.

  2011cites this paper
• VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse

  2011cites this paper
• [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].

  2011cites this paper
• Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs

  2010cites this paper
• Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons

  2009cites this paper
• Interaction of psychostimulant intake with brain aging: Effects on behavioral capacity, oxidative damage and dopaminergic markers

  2009cites this paper
• 7 Vesicular Neurotransmitter Transporters

  2009cites this paper
• Literature-Related Discovery (LRD)

  2007cites this paper
• Identification of a Gastrin Response Element in the Vesicular Monoamine Transporter Type 2 Promoter and Requirement of 20 S Proteasome Subunits for Transcriptional Activity*

  2007cites this paper
• Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels.

  2007cites this paper
• Vesicular monoamine transporter 2: Role as a novel target for drug development

  2006cites this paper
• Three Types of Tyrosine Hydroxylase-Positive CNS Neurons Distinguished by Dopa Decarboxylase and VMAT2 Co-Expression

  2006cites this paper